Science & Technology — TraumaShield PTSD Prevention
Science & Technology

Mechanism, not hope.

An FDA-approved agent, delivered by a field-ready device, acting on the fear-memory consolidation window. Below: how it works, what it is made of, and the evidence behind it.

Scientific validation

Mechanism of action

Memories are consolidated — not formed — in the hours after trauma. TraumaShield acts on four pathways during that window. Select a pathway to load its model.

Mechanism of action model

Suppress fear learning responses (by reducing the hyper activity in the Amygdala).

Enhances healthy contextual memory (by enhancing hippocampal neuroplasticity).

Enhance GABAergic inhibitory transmission.

View model →

Suppress excitatory NMDA receptor activity.

View model →

Modulate neuroprotective pathways to prevent long-term damage.

View model →
Pathological vs. historical consolidation
Pathological versus historical memory consolidation
The device

Real-time drug‑device intervention for post‑trauma disorder prevention

Time

Administered during the post-trauma “golden hours” to support healthy memory consolidation.

Drug

An FDA-approved compound that helps the patient perceive the event as natural rather than traumatic, allowing it to be remembered as a past, safe experience instead of an ongoing nightmare.

Device

Delivered through a dedicated, disposable, and easy-to-use inhalation device.

TraumaShield drug-device combination — the world's first PTSD prevention protocol
Peer-reviewed evidence

47% reduction in PTSD incidence.
Validated. Peer-reviewed. Reproducible.

Human data · surgical trauma model · 1-month follow-up
12.2%
TraumaShield
23.2%
Standard care
47%
Reduction in
PTSD incidence
*p < 0.05
Preclinical data · SEFL models · freezing behavior
~20%
Treated
~80%
Control

Stress-Enhanced Fear Learning (SEFL) significantly reduced in animal models. Freezing behavior (fear response) reduced from ~80% to ~20% in treated subjects. *p < 0.05

01 · Mechanism
Fear-Memory Consolidation Window

The neuroscientific mechanism explaining why the 0-6 hour window is the only viable prevention point. Memories are consolidated — not formed — in this window, making pharmacological intervention uniquely effective.

02 · Safety
FDA-Approved Agent

Existing safety profile eliminates Phase 1 risk entirely. The repurposed agent has a well-characterized pharmacokinetic and safety profile from prior clinical use.

03 · Evidence
Second Medical Use — Clinically Validated

Backed by independent peer-reviewed studies. 47% reduction confirmed in human surgical trauma data. Reproducible across preclinical SEFL animal models.

"Backed by independent clinical validation and a full scientific package assembled by world-leading experts in psychiatry and neuroscience."
Strategic moats

Protected, fast,
field-ready.

A method-of-use patent, an accelerated regulatory pathway, and a form factor built for the field — three defences that compound.

Patent protected
20-Year Method-of-Use Patent

Exclusive rights secured for the second medical use and combination device architecture.

Regulatory pathway
505(b)(2) Combination Product

Streamlined FDA pathway confirmed, leveraging existing safety data to accelerate time-to-market.

Deployment
Field-Ready Munition Grade

Fits standard IFAK kits. Zero training required. Instant activation for immediate post-trauma care.

TraumaShield intellectual property position

The full scientific
package is available.

Peer-reviewed studies, preclinical datasets and the regulatory dossier are shared with qualified investors and clinical partners on request.

Mechanism of action model